Professor Robyn Guymer from Melbourne, Australia discusses results of the LEAD trial that investigated the use of nanopulase laser for dry AMD.

Full reference of the article:

Guymer, R. H., Wu, Z., Hodgson, L. A. B., Caruso, E., Brassington, K. H., Tindill, N., . . . Laser Intervention in Early Stages of Age-Related Macular Degeneration Study, G. (2018). Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial. Ophthalmology. doi:10.1016/j.ophtha.2018.09.015

Dr. Ozkok describes his publication on the association of Red Blood Cells Distribution Width (RDW) and vision in patients with Central or Branch Retina Vein Occlusion. 

Full Reference of the article:

Ozkok, A., Nesmith, B. L. W., & Schaal, S. (2018). Association of Red Cell Distribution Width Values with Vision Potential in Retinal Vein Occlusion. Ophthalmology Retina, 2(6), 582-586. doi:10.1016/j.oret.2017.09.018

Dr. Jennifer Sun discusses 5-year results of DRCR.net Protocol S that investigated outcomes of treatment of proliferative diabetic retinopathy using traditional PRP laser vs intravitreal ranibizumab injections. 

Full reference:

Gross, J. G., Glassman, A. R., Liu, D., Sun, J. K., Antoszyk, A. N., Baker, C. W., . . . Diabetic Retinopathy Clinical Research, N. (2018). Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2018.3255

Please leave your comments in iTunes or send them to [email protected] 

Dr. Camiel Boon from Leiden University Medical Center (LUMC) and Amsterdam University Medical Centers in Amsterdam discusses the results of his research work on the comparison of half-dose PDT vs micropulse laser to treat central serous chorioretinopathy.

Full reference of the discussed article:

van Dijk, E. H. C., Fauser, S., Breukink, M. B., Blanco-Garavito, R., Groenewoud, J. M. M., Keunen, J. E. E., . . . Boon, C. J. F. (2018). Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. Ophthalmology. doi:10.1016/j.ophtha.2018.04.021

Dr. Chakravarthy from Belfast, UK discusses a secondary analysis of the IVAN Trial to compare effects of intravitreal anti-VEGF therapy on serum VEGF levels with possible trends in system adverse events in the context of wet AMD.

Full reference:

Chris A.Rogers, Lauren J.Scott, Barnaby C.Reeves, Susan Downes, Andrew J.Lotery, Andrew D.Dick, Usha Chakravarthy for IVAN trial investigators, Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events, Ophthalmology Retina, Feb. 2018

http://dx.doi.org/10.1016/j.oret.2017.05.015

Dr. Charles Wykoff discusses results of DRCR protocol T ancillary study on plasma free VEGF concentrations after different intravitreal anti-VEGF injections for diabetic macular edema.

Full reference of the discussed article:

Jampol, L. M., A. R. Glassman, D. Liu, L. P. Aiello, N. M. Bressler, E. J. Duh, S. Quaggin, et al. "Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema." Ophthalmology  (Mar 7 2018).

Dr. Sean Adrean discusses his retrospective analysis of patients with wet AMD who had over 50 anti-VEGF injections.

Full reference of the discussed article:

Adrean, S. D., S. Chaili, H. Ramkumar, A. Pirouz, and S. Grant. "Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-Vegf Injections Using a Treat-Extend-Stop Protocol." Ophthalmology  (Feb 10 2018).

Dr. Mark Humayun discusses the results of his team's work on implantation of RPE stems cells placed on a bioengineered surface for dry AMD. 

Full reference of the article:

Kashani, A. H., Lebkowski, J. S., Rahhal, F. M., Avery, R. L., Salehi-Had, H., Dang, W., . . . Humayun, M. S. (2018). A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci Transl Med, 10(435). doi:10.1126/scitranslmed.aao4097

Dr. David Almeida discusses the result of his group's large retrospective analysis of management and outcomes of 40 cases of endophthalmitis from over 258,000 intravitreal anti-VEGF injections. 

Full reference:

Xu, K., Chin, E. K., Bennett, S. R., Williams, D. F., Ryan, E. H., Dev, S., . . . Almeida, D. R. P. (2018). Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes. Ophthalmology. doi:10.1016/j.ophtha.2018.01.022

Dr. Rajeev Muni describes the results of his research on the correlation of cytokine levels (VEGF, ICAM, etc) and the anatomical response to intravitreal ranibizumab for the treatment of diabetic macular edema.

Full reference of the article:

Hillier, R. J., Ojaimi, E., Wong, D. T., Mak, M. Y. K., Berger, A. R., Kohly, R. P., . . . Muni, R. H. (2018). Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2018.0179

Please send leave your comments in iTunes or send to [email protected]